Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD Cosentyx® - Anti IL-17 Study Indication Phase Patients Primary Outcome Measures NCT04179175 (CAIN457M2301E1) Hidradenitis Suppurativa (HS) Phase 3 745 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Arms Intervention Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Patients with moderate to severe hidradenitis suppurativa completing either of the core trials AIN457M2301 (NCT 0313632) or AIN567M2302 (NCT03713619) Target Patients Read-out Milesstone(s) 2025 Publication Study design SHSA 2020 NCT04181762 SELUNE (CAIN457Q12301) Lupus Nephritis Phase 3 460 Proportion of subjects achieving protocol-defined CRR Secukinumab 300 mg s.c. Placebo s.c. Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co- existing class V features) 2026 2026 78 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation